Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $1.2 million.

  • Foghorn Therapeutics' Change in Accured Expenses fell 76.72% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 175.47%. This contributed to the annual value of -$564,000 for FY2024, which is 68.61% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Change in Accured Expenses of $1.2 million as of Q3 2025, which was down 42.69% from $2.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' Change in Accured Expenses' 5-year high stood at $5.0 million during Q3 2024, with a 5-year trough of -$2.8 million in Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$304,000 (2024), whereas its average is -$144,727.
  • Per our database at Business Quant, Foghorn Therapeutics' Change in Accured Expenses plummeted by 15,247.06% in 2021 and then spiked by 764.14% in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Change in Accured Expenses (Quarterly) stood at $2.4 million in 2021, then crashed by 62.75% to $894,000 in 2022, then tumbled by 62.86% to $332,000 in 2023, then tumbled by 829.22% to -$2.4 million in 2024, then tumbled by 76.72% to $1.2 million in 2025.
  • Its Change in Accured Expenses was $1.2 million in Q3 2025, compared to $2.0 million in Q2 2025 and -$2.4 million in Q1 2025.